Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358557 | 0.86 | NPC1 (0.63) | LOXL2NPC1RAB9AGAAMAPK1 | |
| SCHEMBL584581 | 0.85 | LOXL2 (0.74) | LOXL2NPC1RAB9AGAAHDAC6 | |
| SCHEMBL30471048 | 0.84 | LOXL2 (0.72) | LOXL2NPC1RAB9AGAAHDAC6 | |
| SCHEMBL201922 | 0.84 | LOXL2 (0.72) | LOXL2NPC1RAB9AGAAHDAC6 | |
| SCHEMBL21104587 | 0.82 | LOXL2 (0.70) | LOXL2GAAHDAC6SMN1; SMN2NPSR1 | |
| SCHEMBL7461310 | 0.82 | LOXL2 (0.70) | LOXL2NPC1RAB9AGAAHDAC6 | |
| SCHEMBL3248813 | 0.82 | LOXL2 (1.00) | LOXL2NPC1RAB9AGAAHDAC6 | |
| SCHEMBL30209080 | 0.82 | LOXL2 (1.00) | LOXL2NPC1RAB9AGAAHDAC6 | |
| SCHEMBL17229258 | 0.81 | LOXL2 (0.64) | LOXL2NPC1RAB9AGAAMAPK1 | |
| SCHEMBL16425158 | 0.81 | LOXL2 (0.64) | LOXL2NPC1RAB9AGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047589-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11230542-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2022-01-25 | — | — | US | disclosed |
| CN-113105412-A | Method for synthesizing benzothiazole compound | 天津理工大学 | 2021-07-13 | — | — | CN | disclosed |
| WO-2019055540-A1 | COMPOUNDS AS RAS INHIBITORS AND USE THEREOF | D.E. SHAW RESEARCH, LLC (US) | 2019-03-21 | — | — | WO | disclosed |
| EP-2970158-B1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | BIOELECTRON TECH CORP (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| CN-103664821-B | A kind of benzothiazole compound preparation method based near amino thiophenols cyclisation | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2015-10-28 | — | — | CN | disclosed |
| CN-103664821-A | Preparation method of benzothiazole compound based on aminothiophenol cyclization | UNIV DALIAN TECH | 2014-03-26 | — | — | CN | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8268871-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7795282-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | LOXL2 3703/4885NPC1 2305/4885RAB9A 3217/4885 |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | LOXL2 3109/4885NPC1 1689/4885RAB9A 1317/4885 |
| US-11230542-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | LOXL2 3957/4885NPC1 2384/4885RAB9A 3893/4885 |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | LOXL2 2893/4885NPC1 1188/4885RAB9A 478/4885 |
| US-20230047589-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | LOXL2 3957/4885NPC1 2384/4885RAB9A 3893/4885 |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF2C, KIFC1 | LOXL2 4456/4885NPC1 512/4885RAB9A 1590/4885 |
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | NQO1, COQ8A, NDUFAB1 | LOXL2 1902/4885NPC1 551/4885RAB9A 796/4885 |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | LOXL2 2467/4885NPC1 1884/4885RAB9A 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.